Show simple item record

dc.contributor.authorMijuskovic, M
dc.contributor.authorSaunders, EJ
dc.contributor.authorLeongamornlert, DA
dc.contributor.authorWakerell, S
dc.contributor.authorWhitmore, I
dc.contributor.authorDadaev, T
dc.contributor.authorCieza-Borrella, C
dc.contributor.authorGovindasami, K
dc.contributor.authorBrook, MN
dc.contributor.authorHaiman, CA
dc.contributor.authorConti, DV
dc.contributor.authorEeles, RA
dc.contributor.authorKote-Jarai, Z
dc.date.accessioned2018-07-18T13:29:02Z
dc.date.issued2018-07-03
dc.identifier.citationBritish journal of cancer, 2018, 119 (1), pp. 96 - 104
dc.identifier.issn0007-0920
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2090
dc.identifier.eissn1532-1827
dc.identifier.doi10.1038/s41416-018-0141-7
dc.description.abstractBACKGROUND: Prostate cancer (PrCa) demonstrates a heterogeneous clinical presentation ranging from largely indolent to lethal. We sought to identify a signature of rare inherited variants that distinguishes between these two extreme phenotypes. METHODS: We sequenced germline whole exomes from 139 aggressive (metastatic, age of diagnosis < 60) and 141 non-aggressive (low clinical grade, age of diagnosis ≥60) PrCa cases. We conducted rare variant association analyses at gene and gene set levels using SKAT and Bayesian risk index techniques. GO term enrichment analysis was performed for genes with the highest differential burden of rare disruptive variants. RESULTS: Protein truncating variants (PTVs) in specific DNA repair genes were significantly overrepresented among patients with the aggressive phenotype, with BRCA2, ATM and NBN the most frequently mutated genes. Differential burden of rare variants was identified between metastatic and non-aggressive cases for several genes implicated in angiogenesis, conferring both deleterious and protective effects. CONCLUSIONS: Inherited PTVs in several DNA repair genes distinguish aggressive from non-aggressive PrCa cases. Furthermore, inherited variants in genes with roles in angiogenesis may be potential predictors for risk of metastases. If validated in a larger dataset, these findings have potential for future clinical application.
dc.formatPrint-Electronic
dc.format.extent96 - 104
dc.languageeng
dc.language.isoeng
dc.publisherSPRINGERNATURE
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectHumans
dc.subjectProstatic Neoplasms
dc.subjectNeoplasm Metastasis
dc.subjectGenetic Predisposition to Disease
dc.subjectNeovascularization, Pathologic
dc.subjectCell Cycle Proteins
dc.subjectBRCA2 Protein
dc.subjectNuclear Proteins
dc.subjectDNA Repair
dc.subjectPolymorphism, Single Nucleotide
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.subjectGenetic Association Studies
dc.subjectAtaxia Telangiectasia Mutated Proteins
dc.subjectWhole Exome Sequencing
dc.titleRare germline variants in DNA repair genes and the angiogenesis pathway predispose prostate cancer patients to develop metastatic disease.
dc.typeJournal Article
dcterms.dateAccepted2018-05-17
rioxxterms.versionofrecord10.1038/s41416-018-0141-7
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2018-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfBritish journal of cancer
pubs.issue1
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Genetics and Epidemiology/Oncogenetics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Oncogenetics
pubs.organisational-group/ICR/Students
pubs.organisational-group/ICR/Students/PhD and MPhil
pubs.organisational-group/ICR/Students/PhD and MPhil/18/19 Starting Cohort
pubs.publication-statusPublished
pubs.volume119
pubs.embargo.termsNot known
icr.researchteamOncogenetics
dc.contributor.icrauthorSaunders, Edward
dc.contributor.icrauthorBrook, Mark
dc.contributor.icrauthorEeles, Rosalind
dc.contributor.icrauthorKote-Jarai, Zsofia


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0